Brokerages Set Beam Therapeutics Inc. (NASDAQ:BEAM) PT at $47.17

Beam Therapeutics Inc. (NASDAQ:BEAM) has been assigned an average rating of “Moderate Buy” from the fourteen analysts that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, three have given a hold recommendation, nine have issued a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $46.8333.

Several brokerages have recently commented on BEAM. Royal Bank Of Canada raised their price target on Beam Therapeutics from $22.00 to $26.00 and gave the company a “sector perform” rating in a research note on Wednesday, February 25th. Wedbush raised their price objective on Beam Therapeutics from $57.00 to $65.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Citigroup lifted their target price on Beam Therapeutics from $64.00 to $68.00 and gave the company a “buy” rating in a research note on Thursday, March 26th. Canaccord Genuity Group began coverage on shares of Beam Therapeutics in a report on Friday, February 20th. They issued a “buy” rating and a $74.00 target price for the company. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Beam Therapeutics in a research report on Monday, April 20th.

Key Stories Impacting Beam Therapeutics

Here are the key news stories impacting Beam Therapeutics this week:

• Negative Sentiment: HC Wainwright reduced Beam Therapeutics’ earnings outlook across several future years, including FY2026 through FY2030, signaling a more cautious view on the company’s long-term profitability. Beam Therapeutics stock page
• Negative Sentiment: The firm also trimmed quarterly EPS estimates for Q2 2026, Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027 and Q4 2027, which may weigh on sentiment near term. Beam Therapeutics stock page
• Neutral Sentiment: Beam Therapeutics recently reported better-than-expected quarterly results, but the company is still expected to post losses for the full year, so investors remain focused on its ability to narrow deficits over time. Beam Therapeutics stock page

Insiders Place Their Bets

In other news, insider Christine Bellon sold 5,956 shares of the firm’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $146,398.48. Following the completion of the sale, the insider owned 109,711 shares of the company’s stock, valued at $2,696,696.38. This trade represents a 5.15% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Amy Simon sold 6,700 shares of the business’s stock in a transaction on Wednesday, April 1st. The stock was sold at an average price of $24.58, for a total value of $164,686.00. Following the transaction, the insider owned 102,735 shares in the company, valued at approximately $2,525,226.30. This trade represents a 6.12% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders sold 79,544 shares of company stock valued at $1,899,942. Company insiders own 3.80% of the company’s stock.

Institutional Trading of Beam Therapeutics

Several large investors have recently bought and sold shares of BEAM. Renaissance Technologies LLC increased its position in shares of Beam Therapeutics by 228.2% in the 1st quarter. Renaissance Technologies LLC now owns 513,578 shares of the company’s stock valued at $12,239,000 after acquiring an additional 357,078 shares during the period. First Trust Advisors LP lifted its position in Beam Therapeutics by 111.0% during the 1st quarter. First Trust Advisors LP now owns 135,166 shares of the company’s stock worth $3,221,000 after acquiring an additional 71,110 shares during the period. Himension Capital Singapore PTE. LTD. purchased a new stake in Beam Therapeutics during the 1st quarter valued at about $1,480,000. Hollencrest Capital Management purchased a new stake in Beam Therapeutics during the 1st quarter valued at about $43,000. Finally, Dimensional Fund Advisors LP increased its holdings in shares of Beam Therapeutics by 10.6% in the first quarter. Dimensional Fund Advisors LP now owns 2,154,575 shares of the company’s stock valued at $51,327,000 after purchasing an additional 206,696 shares during the period. Hedge funds and other institutional investors own 99.68% of the company’s stock.

Beam Therapeutics Trading Down 5.4%

Beam Therapeutics stock opened at $27.93 on Friday. The business’s fifty day moving average is $27.50 and its 200 day moving average is $27.17. The stock has a market capitalization of $2.87 billion, a PE ratio of -41.07 and a beta of 2.26. The company has a debt-to-equity ratio of 0.09, a current ratio of 16.99 and a quick ratio of 16.99. Beam Therapeutics has a one year low of $15.35 and a one year high of $36.44.

Beam Therapeutics (NASDAQ:BEAM) last issued its quarterly earnings results on Thursday, May 7th. The company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($1.03) by $0.12. Beam Therapeutics had a negative net margin of 39.66% and a negative return on equity of 29.00%. The company had revenue of $31.74 million for the quarter, compared to the consensus estimate of $10.98 million. During the same period in the prior year, the firm posted ($1.23) EPS. The firm’s revenue was up 323.2% compared to the same quarter last year. On average, sell-side analysts predict that Beam Therapeutics will post -4.23 EPS for the current year.

About Beam Therapeutics

Beam Therapeutics, Inc (NASDAQ: BEAM) is a biotechnology company dedicated to developing precision genetic medicines through its pioneering base editing platform. Headquartered in Cambridge, Massachusetts, with additional research facilities in Philadelphia, the company focuses on engineering molecular editors capable of making precise single-nucleotide changes in DNA. By harnessing its proprietary base editing technology, Beam aims to correct or disrupt disease-causing genetic variants at their source, offering the potential for novel therapies in areas with significant unmet medical need.

Founded in 2017 as a spin-out from Harvard University and the Broad and Whitehead Institutes, Beam was co-founded by leading academic researcher David R.